为了正常的体验网站,请在浏览器设置里面开启Javascript功能!
首页 > 文献

文献

2013-10-02 24页 pdf 1MB 31阅读

用户头像

is_821623

暂无简介

举报
文献 Nicholls M. John Chapman, Raimund Erbel, Joel S. Raichlen, Kiyoko Uno, Yu Kataoka and Stephen J. Rishi Puri, Steven E. Nissen, Peter Libby, Mingyuan Shao, Christie M. Ballantyne, Phillip J. Barter, Statin Therapy Coronary Atheroma Regression and Cardiovascular E...
文献
Nicholls M. John Chapman, Raimund Erbel, Joel S. Raichlen, Kiyoko Uno, Yu Kataoka and Stephen J. Rishi Puri, Steven E. Nissen, Peter Libby, Mingyuan Shao, Christie M. Ballantyne, Phillip J. Barter, Statin Therapy Coronary Atheroma Regression and Cardiovascular Events Following Maximally Intensive C-Reactive Protein, but not Low-Density Lipoprotein Cholesterol Levels, Associate with Print ISSN: 0009-7322. Online ISSN: 1524-4539 Copyright © 2013 American Heart Association, Inc. All rights reserved. is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231Circulation published online September 16, 2013;Circulation. http://circ.ahajournals.org/content/early/2013/09/16/CIRCULATIONAHA.113.004243 World Wide Web at: The online version of this article, along with updated information and services, is located on the http://circ.ahajournals.org//subscriptions/ is online at: Circulation Information about subscribing to Subscriptions: http://www.lww.com/reprints Information about reprints can be found online at: Reprints: document. Permissions and Rights Question and Answer available in the Permissions in the middle column of the Web page under Services. Further information about this process is Once the online version of the published article for which permission is being requested is located, click Request can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office.Circulation Requests for permissions to reproduce figures, tables, or portions of articles originally published inPermissions: at University of Michigan--Ann Arbor on September 18, 2013http://circ.ahajournals.org/Downloaded from DOI: 10.1161/CIRCULATIONAHA.113.004243 1 C-Reactive Protein, but not Low-Density Lipoprotein Cholesterol Levels, Associate with Coronary Atheroma Regression and Cardiovascular Events Following Maximally Intensive Statin Therapy Running title: Puri et al.; Statins, CRP, plaque progression and MACE Rishi Puri, MBBS1; Steven E. Nissen, MD1; Peter Libby, MD2; Mingyuan Shao, MS3; Christie M. Ballantyne, MD4; Phillip J. Barter, MBBS, PhD5; M. John Chapman, PhD, DSc6; Raimund Erbel, MD7; Joel S. Raichlen, MD8; Kiyoko Uno, MD, PhD1; Yu Kataoka, MD1; Stephen J. Nicholls, MBBS, PhD1,9 1Dept of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH; 2Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA; 3C5Research, Cleveland Clinic, Cleveland, OH; 4Section of Cardiovascular Research, Baylor College of Medicine, and the Methodist DeBakey Heart and Vascular Center, Houston, TX; 5Centre for Vascular Research, University of New South Wales, Sydney, Australia; 6INSERM Dyslipidaemia and Atherosclerosis Research Unit, Hôpital de la Pitié, Paris, France; 7West German Heart Center, Essen, Germany; 8AstraZeneca, Wilmington, DE; 9South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia Address for Correspondence: Stephen J. Nicholls, MB, BS, PhD South Australian Health and Medical Research Institute Level 9, 121 King William St Adelaide, SA, 5001, Australia Tel: 61-8-81164432 Fax: 61-8-81164432 E-mail: stephen.nicholls@sahmri.com Journal Subject Codes: Atherosclerosis:[135] Risk factors, Atherosclerosis:[150] Imaging, Atherosclerosis:[90] Lipid and lipoprotein metabolism, Treatment:[122] Secondary prevention Raimund Erbel, MD ; Joel S. Raichlen, MD ; Kiyoko Uno, MD, PhD ; Yu Katataoaoaokaka, , MDMD ;; Stephen J. Nicholls, MBBS, PhD1,9 1DeDeptptp oooff f CaCaardrdr iooovavavascs ular Medicine, Cleveland CCliliininn c, Cleveland, OHH;; 2CaCC rdiovascular Division, BrBrBrigigighhaham m anananddd WoWoW mmen’s Hosppital, Boston, MA; 333C5C5Research, Clleveve ellananddd Clinic, Cleveland, OH; 444Seeectc ion off CCCararardididiovovvasasascucuculalalarr r ReReResesesearararchchh,, BaBaB ylylylororor CCoollleeegee ooof f f MeMeMedidiccicinenee, , anananddd tthe e MeMeMethththododo isisst tt DeDeDeBaBaBakekek y HHeHeart and VaVassscuuularr CCCenteter,r, HHououustststonnn, TTX;;; 5CCennntrree fororor VVVaaasccculalaar RReseeearrcrch,h,h, UUUniniveveersssitityyy oofof NNewww SoSoSoutuu h Walelees,ss SSydyddneyy, Ausustrtralala iaia; 66ININI SESEERMMM DDysysliippidadadaeememiiaa aanddd AAAtherrrosssclcleere oososisi RRReeseseaaarccch UnUnUnit, HôHôôpipipitatatalll dedede lla a PiPiPititié,é,é PPPararisisis,, Frrananancee;;; 777WeWeestst GGGererermamaman nn HeHeHeararart t CeCeCentntntereer, EsEsEssessen,n,n, GGGerere mamamanynyny; ; ; 888AsAsAsttrtraZaZaZenenenececca,a,a WiWiWilmlmlmininingtgtgtononon,, DEDEDE;;; 9SoSoSoutututhhh AuAuAustststrararalililiananan HHHeaeaealtltlthhh anananddd MeMeMedididicacacalll ReReResesesearararchchch IIInsnsnstitititutututetete,, UnUnUnivivivererersisisitytyty ooofff AdAdAdelllaiaiaidedede,, AdAdAdelelelaiaiaidedede,, AuAuAustststrararalililiaaa at University of Michigan--Ann Arbor on September 18, 2013http://circ.ahajournals.org/Downloaded from DOI: 10.1161/CIRCULATIONAHA.113.004243 2 Abstract Background—Baseline C-reactive protein (CRP) levels predict major adverse cardiovascular events [MACE; death, myocardial infarction, stroke, coronary revascularization and hospitalization for unstable angina]. The association between changes in CRP levels with plaque progression and MACE in the setting of maximally intensive statin therapy is unknown. Methods and Results—SATURN employed serial intravascular ultrasound (IVUS) measures of coronary atheroma volume in patients treated with rosuvastatin 40 mg or atorvastatin 80 mg for 24 months. The treatment groups did not differ significantly in the change from baseline of percent atheroma volume (PAV) on IVUS, CRP-modulating effects or MACE rates, thus allowing for a (prespecified) post-hoc analysis to test associations between changes in CRP levels with coronary disease progression and MACE. Patients with non-increasing CRP levels (n=621) had higher baseline [2.3 (1.1, 4.7) vs. 1.1 (0.5, 1.8) mg/L, p<0.001] and lower follow-up CRP levels [0.8 (0.5, 1.7) vs. 1.6 (0.7, 4.1) mg/L, p<0.001] versus those with increasing CRP levels (n=364). Multivariable analysis revealed a non-increasing CRP level to independently associate with greater PAV regression (p=0.01). While the (log) change in CRP did not associate with MACE [HR 1.18 (95% CI 0.93, 1.50), p=0.17], the (log) on-treatment CRP associated significantly with MACE [HR 1.28 (95% CI 1.04, 1.56, p=0.02). On-treatment LDL-C levels did not correlate with MACE [HR 1.09 (95% CI 0.88, 1.35, p=0.45). Conclusions—Following 24 months of potent statin therapy, on-treatment CRP levels associated with MACE. Inflammation may be an important driver of residual cardiovascular risk in patients with coronary artery disease despite aggressive statin therapy. Clinical Trial Registration Information—ClinicalTrials.gov. Identifier: NCT000620542. Key words: statin, inflammation, low-density lipoprotein cholesterol, intravascular ultrasound, atherosclerosis, C-reactive protein y p g gg n=621) had higher baseline [2.3 (1.1, 4.7) vs. 1.1 (0.5, 1.8) mg/L, p<0.001] and d lolloweww rr r fofofollllllowowow-u- pp CRP levels [0.8 (0.5, 1.7) vs. 1.6 (0.7, 4.1) mg/L, p<0.001] versus those with increasing CRP evels (n=364). Multivariable analysis revealed a non-increasing CRP level to independently asasssosocciciatate wiwiwiththth ggrereatatere PPAVAV regegreessioi n n (pp=0.01)1).. WhWhW ile ththe e (l( ogg)) chchc anngege iin CRRPP did non t t asa sociate wwithhh MACE [HHR RR 111.181818 ((959595%% % CICIC 00.9.9.93,3,3 11.5550), p===0.1177]], thhheee (l(logogog)) ononn-tttreeatatmemem ntnt CCCRPRP aaasssssococciaaatetteddd iigngng ififi iccantly y y wiwiw thhh MMAACACEE [HHHR R R 1.1.28288 ((9955%% % CCII 111.0.044, 11.5.566,6, pp==0..002)2). OOnOn-trrreaatatmmmentntn LLDLDLDL-CCC llevevelells did not t cocorrr elelatatee wiwitht MMACA EE [H[HR R 11.0909 (95% % CICI 00.888,8 1.335,5 pp=0=0.4.45).. Conclusionnsss——FoFoFollllllowowowininng g 242424 mmononnththhss ofoff ppotototenenentt t stststatatininin tttheerarrapypyy, onoon-trereeatatatmememennnt tt CRCRCRPP P leleevevev lslsl associateddd at University of Michigan--Ann Arbor on September 18, 2013http://circ.ahajournals.org/Downloaded from DOI: 10.1161/CIRCULATIONAHA.113.004243 3 Statin-mediated cholesterol lowering improves clinical outcomes. But despite this, many individuals demonstrate atheroma progression,1 and many such patients experience further cardiovascular events. Randomized clinical trials employing the best contemporary medical therapies demonstrate, at most, relative risk reductions of the order of 30-40%. This highlights a significant degree of residual cardiovascular risk experienced by a large proportion of individuals prescribed statins for secondary clinical prevention.2 Accordingly, there is a need to identify novel targets and therapeutic strategies to effectively combat this residual risk. Multiple avenues of research implicate inflammation as a factor involved in the initiation, progression and instability of atherosclerotic plaques.3, 4 Elevations of serum inflammatory biomarkers consistently associate with the risk of experiencing a cardiovascular event.5, 6 C- reactive protein (CRP), in particular, has been extensively investigated, and the prognostic utility of baseline CRP levels is now considered by some, to be equivalent to that of serum cholesterol levels.7, 8 While many benefits of statins are attributed to cholesterol lowering, both coronary atheroma regression9 and clinical event reductions10 have also been shown independently to correlate with statin-mediated CRP lowering. Yet there remains an ongoing debate as to whether the effects of statin-mediated CRP lowering are simply a function of parallel changes in low- density lipoprotein cholesterol (LDL-C), or follow a separate mechanistic pathway. The prognostic benefit of CRP in statin-treated patients who achieve LDL-C levels <70 mg/dL, is uncertain.11 SATURN (Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin; ClinicalTrials.gov number, NCT000620542) was the first head-to-head comparison of the anti-atherosclerotic effect of two potent statin agents, each prescribed at their maximal approved dose, on coronary atherosclerosis progression.12 Treatment biomarkers consistently associate with the risk of experiencing a cardiovascular eeevenee tt..5,5, 5 666 CCC-- eactive protein (CRP), in particular, has been extensively investigated, and the prognostic utility off bbbasasaselelelininineee CRCRC PP lelelevvels is now considered by sommeme,, to be equivaleeentnn to o thththata of serum cholesterol eeveeelsl .7, 8 Whiilele mmmananyy bebeenenenefifiitststs oof f ststs aaatitinsns aree attttribbubutted totoo cchohoh lelessttterrrol l lololowweeriringngng,, bobooththth ccoorronononararyy y attheheheroroomamam rrregegegreresssssiooonn99 aanndd ccliinnin cacaalll evevevenennt t rerereduduductttioioionnsns1100 hhhavavveee alaalsooo bbeeeee nnn shshs owowownn ininindededepepependndndennntlyy y totoo correlate withthh sstatat tititin-n-n mememedid atatatededed CCCRPRPR lllowowwerererinining.g.g. YYYetetet thththerere e e rerer mamamainnns s s ananan ooongngngoioioingngng ddebebebatatate e e asasas to whetherrr at University of Michigan--Ann Arbor on September 18, 2013http://circ.ahajournals.org/Downloaded from DOI: 10.1161/CIRCULATIONAHA.113.004243 4 with both agents was associated with regression of coronary atheroma, although there was no significant difference between the two groups in the primary efficacy end point of change in percent atheroma volume (PAV); nor was there a difference in safety or clinical event rates between each treatment group. The primary objective of this prespecified post hoc analysis was to examine the prognostic effect of changes in CRP levels on both coronary atheroma progression and major adverse cardiovascular events (MACE) in patients following 24 months of maximally intensive statin therapy. Methods Patient selection The design of SATURN has been previously described.13 Briefly, patients with angiographically demonstrable coronary disease and LDL-C <116 mg/dL following a 2-week treatment period with atorvastatin 40 mg or rosuvastatin 20 mg daily were re-randomized and treated for 24- months with atorvastatin 80 mg or rosuvastatin 40 mg daily. Subjects underwent intravascular ultrasound (IVUS) imaging of a coronary artery at baseline and after 104 weeks of treatment. Acquisition and analysis of intravascular coronary imaging The presence of at least a single lumen stenosis of >20% angiographic diameter stenosis severity in an epicardial coronary artery at the time of a clinically indicated coronary angiogram was necessary for enrolment eligibility. IVUS was performed at baseline in a single, native coronary artery with no lumen stenosis of >50% severity, which had not undergone revascularization and was not considered to be the culprit vessel of a prior myocardial infarction (MI). Images were screened by the Atherosclerosis Imaging Core Laboratory of the Cleveland Clinic Center for Clinical Research for quality, and those patients whose baseline imaging met these requirements, Patient selection The design of SATURN has been previously described.13 Briefly, patients with angiographically deemomomonsnsnsttrtrababablelele cororroononary disease and LDL-C <11666 mmg/dL followinng gg a 2-2--wweweek treatment period wwithhh atorvastaatitiinnn 4440 mmmg ororr rrosososuuvuvasasastataatitinnn 220 mgmgmg daiiilyyy wwerereree reree-rrrananddodomimizezeedd anannddd ttrtreaeattet d d d fofofor 242424-- momoontntnthshshs wwititth h h atatororrvavaaststaatatinnn 880 mgmgmg ooor rr rrorosusuuvavavastststaaatininn 44000 mgmgmg dddaaan ilililyyy. SSSubububjejeectctctss uunundederwrwrwenene t t ininintttravavvasasscuculllarr ultrasound ((IVIVVUSUSUS)) ) imimimagagaginnggg ofofo aaa cccororrooonaaaryryry aartrtr ererery y y atatat bbbasasa elellininine ee ananand d d afaa teteer r r 101010444 wewew ekekksss ofofof ttrerer atment. ff at University of Michigan--Ann Arbor on September 18, 2013http://circ.ahajournals.org/Downloaded from DOI: 10.1161/CIRCULATIONAHA.113.004243 5 were eligible for randomization. Following 104 weeks of treatment, patients underwent a second IVUS of the same artery. Anatomically matched arterial segments were selected for analysis on the basis of proximal and distal landmarks. Cross-sectional images spaced 1mm apart were selected for analysis, with lumen and external elastic membrane (EEM) leading edges defined by manual planimetry. Plaque area was determined as the area between these leading edges. Percent atheroma volume (PAV), a measure of plaque burden, was calculated as previously described.14 Change in plaque burden was calculated as the PAV at 104 weeks minus the corresponding PAV at baseline. Plaque regression was defined as any decrease in PAV from baseline. The post-hoc analyses presented here pooled results from both treatment groups; as in SATURN, they did not differ in the primary efficacy endpoint of the change in PAV from baseline, and the average on- treatment CRP levels were not different between the rosuvastatin- and atorvastatin-treated groups. Statistical analysis Continuous variables were reported as mean ± SD if normally distributed and as median (interquartile range) if non-normally distributed. Demographics, baseline clinical characteristics, follow-up medications, baseline ultrasonic and laboratory biochemical data were compared between those who had an increase in average on-treatment CRP levels from baseline, against those whose on-treatment CRP levels did not increase. Two-sample t-tests were used for normally distributed continuous variables, Wilcoxon rank-sum tests for non-normally distributed continuous variables, and chi-square tests for categorical variables. Serial changes in IVUS measurements were analyzed by analysis of variance (ANOVA), adjusting for their baseline counterparts, and were reported as least-squares mean ± SE. Given the significant difference observed for change in PAV between those whose CRP increased versus those whose CRP did differ in the primary efficacy endpoint of the change in PAV from baseline, and d tththe ee avvverereragagageee onon- reatment CRP levels were not different between the rosuvastatin- and atorvastatin-treated grgrououupspsps.. SStStatattisi tical annalalyyysiiis CoCoontntntinininuouoususs vvvarariaiaabblleses wweereree reeepopoportrtrtededed aas s mememeananan ±±± SSSDDD iifif nnnororrmamamally y y didiisttririribububuttteddd anannd d asasa mmmeeediaiaan n interquartilee rrrananangegege))) ififf nnnonnn-n-nnoroo mamamallllyy y diiiststs ririribububuteteted.d.d DDDememmogoggrararaphphphicccs,s,s, bbasasaseleleliinenene ccclilil niniicacacal l chchcharara acteristics,, at University of Michigan--Ann Arbor on September 18, 2013http://circ.ahajournals.org/Downloaded from DOI: 10.1161/CIRCULATIONAHA.113.004243 6 not increase, a multivariable ANOVA analysis was undertaken to assess for its association with changes in CRP levels after controlling for clinical factors. Partial correlation analyses were performed to assess for relationships between change in CRP and lipid parameters, or change in PAV. A multivariable logistic regression model was constructed for defining important predictors of any reduction in CRP from baseline. A multivariable Cox proportional hazards model was derived to identify clinical factors that were associated with MACE, (defined as cardiovascular death, non-fatal MI, non-fatal stroke, coronary revascularization or hospitalization for unstable angina), along with examining the effect of CRP (change in CRP and on-treatment CRP levels) on MACE. To create these multivariable models, demographic data and clinical characteristics were entered into a multivariable logistic or Cox model (with CRP forced into this model) for variable selection with bootstrap re-sampling (1000 iterations and a P value criterion of 0.1 for retention). Those variables having a 40% or more probability of retention were entered into a second logistic or Cox model with the stepwise model selection procedure. The significance level to enter and keep a variable was set at 0.05. For the Cox model, the risk factors met the proportional hazards assumption by plotting the log of the negative log of their estimated survival distribution, log(– log(S(t))), versus time, and the linearity assumption was assessed and satisfied for all continuous variables by plotting the log hazard ratio against the continuous variable as well as testing the linear hypotheses. The selected covariates formed the covariate set for the final multivariable logistic model for on-treatment CRP or the final multivariable Cox model for MACE. Given the significant association between on-treatment CRP levels and MACE, further evaluations were conducted by performing log-rank tests with Kaplan-Meier figures and unadjusted and adjusted Cox proportional hazards regressions with hazard ratio (HR) and associated 95% confidence multivariable models, demographic data and clinical characteristics were entered d d innntotot aaa multivariable logistic or Cox model (with CRP forced into this model) for variable selection withd boootototstststrararapp rerere-s-ssammmplplplining (1000 iterations and a P vavavaluluee criterion of 000.1 ffororor rrrete ention). Those vvariiiaba les haviingng aa 40%0%0% ooorr r momomorrere ppprororobababibillity offf retteennntiooon n weweereee eennteerreded iiintntoo a a a seseecocondndnd lllogoggisssti
/
本文档为【文献】,请使用软件OFFICE或WPS软件打开。作品中的文字与图均可以修改和编辑, 图片更改请在作品中右键图片并更换,文字修改请直接点击文字进行修改,也可以新增和删除文档中的内容。
[版权声明] 本站所有资料为用户分享产生,若发现您的权利被侵害,请联系客服邮件isharekefu@iask.cn,我们尽快处理。 本作品所展示的图片、画像、字体、音乐的版权可能需版权方额外授权,请谨慎使用。 网站提供的党政主题相关内容(国旗、国徽、党徽..)目的在于配合国家政策宣传,仅限个人学习分享使用,禁止用于任何广告和商用目的。

历史搜索

    清空历史搜索